OIT, SLIT, biologics usher in new era in food allergy treatment

Food allergy management is shifting from passive strategies — such as avoidance, carrying epinephrine and hope — to proactive interventions. Most patients and families are aware of strict avoidance and emergency plans. But today, evidence-based tools like oral immunotherapy, sublingual immunotherapy (SLIT) and omalizumab (Xolair; Genentech, Novartis) offer new hope for those burdened